BeyondSpring (NASDAQ: BYSI) Enter Co-development And Commercialization Agreement With Jiangsu Hengrui...

0
BeyondSpring (NASDAQ: BYSI)  has announced an exclusive co-development and commercialization agreement with Jiangsu Hengrui Pharmaceuticals Co. Ltd in Greater China for BeyondSpring’s experimental drug...

Adagio Therapeutics Inc. (NASDAQ: ADGI) Announces That ADG20 Produced A Neutralizing...

0
Adagio Therapeutics Inc. (NASDAQ: ADGI) has summarised recent findings that were published in three different publications showing its flagship monoclonal antibody (mAb), ADG20, had...

Covid Stocks Could Represent Huge Value on Sale (NVAX, OTLC, PFE,...

0
Just when we started to think it was over, Omicron popped up and reminded us that this thing is a whole lot...

Popular News

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Submits sNDA For Approval Of NUPLAZID (pimavanserin)...

0
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has announced the submission of a supplemental new drug application (sNDA) seeking approval from the FDA for its NUPLAZID (pimavanserin)...

MAKE IT MODERN

LATEST REVIEWS

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expects Approval For ORLADEYO In Japan And...

0
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) transitions to a drug launching company to the patients with Hereditary Angioderma. The company expects approval for its ORLADEYO to...

MAKE IT MODERN

PERFORMANCE TRAINING

Preclinical Results for a Novel COVID-19 Vaccine from Soligenix, Inc. Common Stock (NASDAQ:SNGX) are...

0
There are so many programs seeking a vaccine for COVID-19. The global population and the pharmaceutical industry are so expectant of a timely solution....

Selecta Biosciences Inc. (NASDAQ:SELB) Announces Q3 2020 And Offers Business Updates Including Commencement OF...

0
Selecta Biosciences Inc. (NASDAQ:SELB) has announced its Q3 2020 financial results and offered its corporate updates. COMPARE Results Show potential of ImmTOR platform The company’s...

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Reveals Plan To Discontinue Its Vecabrutinib Program

0
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that it will not conduct a Phase 2 clinical trial of its vecabrutinib contrary to previously announced plans. The...

Wall Street calls for SPY December 31 322 Calls

0
The market continues to melt higher but mostly in post/pre-market action. For the past two trading sessions, we have seen a gap...

ChromaDex Corp (NASDAQ:CDXC) Publishes Nutritional Protocol Study Results Showing Improved Recovery Time In COVID-19...

0
ChromaDex Corp (NASDAQ:CDXC) has announced the publication of results of the “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19" study on the medRxiv.org. COVID-19...

MAKE IT MODERN

POPULAR

[/tdc_zone]